{"name":"HUYABIO International, LLC.","slug":"huyabio-international-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"HBI-8000 in combination with nivolumab","genericName":"HBI-8000 in combination with nivolumab","slug":"hbi-8000-in-combination-with-nivolumab","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"Placebo in combination with nivolumab","genericName":"Placebo in combination with nivolumab","slug":"placebo-in-combination-with-nivolumab","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"HBI-8000 in combination with nivolumab","genericName":"HBI-8000 in combination with nivolumab","slug":"hbi-8000-in-combination-with-nivolumab","phase":"phase_3","mechanism":"HBI-8000 is a histone deacetylase (HDAC) inhibitor that enhances immune response when combined with nivolumab, a PD-1 checkpoint inhibitor.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Placebo in combination with nivolumab","genericName":"Placebo in combination with nivolumab","slug":"placebo-in-combination-with-nivolumab","phase":"phase_3","mechanism":"Nivolumab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic renal cell carcinoma","Adenocarcinoma of the bladder","Adenocarcinoma of the esophagus","Adenocarcinoma of the gastroesophageal junction"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOWnU3YnJCYzNuV0Y1RUFWQXpUYlFDTXhGa1hlMnhGRjAyRy01WXNJc05KSmd3RUVKZmV0aUxXWjVPbkV2dkhwb0s1NFdOWTRKSUVvYW8zdFNGSGJQSG5NMzFVQnB3WC12dS1ZQ3VPQnJ0a3pkVzdfTUlaMmV1bEp4VVJ1YS1QTmRBYlpJOGNYQ0c0M3VFcmZyeVhLTnJQcENYcmdkTHNWSmZiam45YlBwRVI0eHhJNkJPX0ZjdE1mZ2hOX0c5dVRNeUZtOU1LUzNpQjJhZ2NwNmpTQlBoSlh0VmpxbDBaWkZQX05YVmlvMFRzZXc2bnBRd2RrS3hNZFphTVhkT2hCc3BMUlliNHd3bXl3ZnJXa3M5NEFqR1ZNdHlERG_SAaMCQVVfeXFMTlp1N2JyQmMzbldGNUVBVkF6VGJRQ014RmtYZTJ4RkYwMkctNVlzSXNOSkpnd0VFSmZldGlMV1o1T25FdnZIcG9LNTRXTlk0SklFb2FvM3RTRkhiUEhuTTMxVUJwd1gtdnUtWUN1T0JydGt6ZFc3X01JWjJldWxKeFVSdWEtUE5kQWJaSThjWENHNDN1RXJmcnlYS05yUHBDWHJnZExzVkpmYmpuOWJQcEVSNHh4STZCT19GY3RNZmdoTl9HOXVUTXlGbTlNS1MzaUIyYWdjcDZqU0JQaEpYdFZqcWwwWlpGUF9OWFZpbzBUc2V3Nm5wUXdka0t4TWRaYU1YZE9oQnNwTFJZYjR3d215d2ZyV2tzOTRBakdWTXR5RERv?oc=5","date":"2026-02-04","type":"trial","source":"Bolsamania","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Bolsamania","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNMmozM3dSajNfR0hyYlVMNU5xYmNTNUhMV1ZUUno3S203Smt4ZVNDZzhVUHJmX1M4WmdMMzV3MmxFeFFjaHB0UERsa3BFUXFZOEZFc2dPS2t1WTVMcmxyc0xLNUh5SXZNT3BMOEJTdXMwUmY2X3B1X0NrV3ZuU1ozMnBCRWZKMTFnc3Zya1BVZw?oc=5","date":"2026-02-04","type":"trial","source":"Yahoo Finance","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Yahoo Finance","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPYmNVUEp3bnpvYXItWDFneERBS2VDeXd2TU5Cc3h4M05lcGlDNFFfd2NnQzc2SFF3a2thODc1OTFkR3pBMkN6SDRWRFMtWG02aGRFWFQ2YXN0RTNFWVFaMkIzd3I4V2x0SXVRMG42Sy1GcG5OSXVDOGx3TE9vYThqaTlBa3VnMUp0VmlXeVlDR1JyYzBm?oc=5","date":"2025-09-30","type":"trial","source":"Yahoo Finance","summary":"Atrial Fibrillation Clinical Trials & Pipeline Overview: Insights into 12+ Leading Companies and 15+ Novel Treatments | DelveInsight - Yahoo Finance","headline":"Atrial Fibrillation Clinical Trials & Pipeline Overview: Insights into 12+ Leading Companies and 15+ Novel Treatments | ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxNalRLOUlrSnpqbkpPZmlJUTVwSlVFYWtuZ2VJN1FjdkxIUDZ5UFpFUmtjM0ptU2h4bVJ2UHEwQnNraGtfYk10MG1MNjNJU2VRX2lhUi1wdHQtTVRFLWphUjgwd1NTbmI2ckZWcHcxVFFaNVN6V3FucUtfRnNXVHBuNkxIcjZib0dKcWs1eXlPMEtPZTFXMG9hNXN5dl82M20wemc1dWNKVXI3bERXdENPckFtLU51Qk1VZmdJTjRTQTRHU0UtU3JHdHpSaS1zSlFxTGd4OUNXSS1yNVhoWFBOZU5ueFNVcW1mY3dkZ01kSHVmd3U3b2xaQWVJVlJNbjFzUGJ0TjY3VVRfb2t5NEQ2MnJKOGd5TFNWQ2REbGRQZ3g3b3l5anBiVTRqaHR2bVdP?oc=5","date":"2025-08-20","type":"pipeline","source":"PR Newswire","summary":"HDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation in Cancer Therapies | DelveInsight - PR Newswire","headline":"HDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQRTM2ZU9vTy01dlV2eGY3VXRUZndGa0c1VlF1ekVPUThQLTE5TTllcktLQjB2VXZXemZOelhHaUh2b0VOUTd0N3JrdG94ck5yU3l5b1d2UUk2TzNiVjV4WXhOU1RtaUlvSlFteXBHMXNnNVFSWEdkUkt5bW5sck12X1hnVzBiT1VSQUxQMmFEeXd5RlowbjN3cDZLUURJWHdkNXZ0MmhWckVaY1N1MElJQ2ZObnZpZDhNcEt6UjFuLUxpQmEwWGFYX013?oc=5","date":"2021-11-30","type":"deal","source":"PR Newswire","summary":"Jemincare Announces the Exclusive License of the Kras Inhibitor to HUYABIO - PR Newswire","headline":"Jemincare Announces the Exclusive License of the Kras Inhibitor to HUYABIO","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}